During his postdoctoral work at The Neuro, Carl studied the major Amyotrophic Lateral Sclerosis disease gene C9ORF72. Through an antibody validation pipeline that he developed, Carl characterized all known C9ORF72 commercial antibodies and found that the most cited antibody does not recognize the protein in any application, but had been cited in dozens of papers cited thousands of times. Carl and Peter McPherson are further developing the pipeline as a technology solution, along with a sustainable business model, to address the antibody liability crisis. The technology platform, called the NeuroSGC Antibody Characterization Platform, is now being formally implemented at The Neuro through the creation of an Antibody Characterization Group. This group functions in partnership with ten leading antibody/KO cell manufacturers who are distinguished by a commitment to reagent quality and contribute significant cash and in-kind resources to the initiative.